Novel bioinformatic classification system for genetic signatures identification in diffuse large B-cell lymphoma

BMC Cancer

Table 1 Baseline features of 342 cases included in this study

Parameters	De novo cases (n = 298)						Relapsed cases	Transformed cases
Parameters	DLBCL, NOS (n = 239)	PMBCL (n = 13)	PCNSL (n = 7)	PCDLBCL-LT (n = 6)	HGBL, NOS (n = 7)	HGBL-DH/TH (n = 26)	DLBCL, NOS (n = 25)	tFL (n = 19)
Gender
Male	131	6	6	2	5	9	16	15
Female	108	7	1	4	2	17	9	4
Age of onset
Median (years)	52	32	59	68	60	50	56	48
COO subtype
GCB	95	6	0	2	4	23	12	14
Non-GCB	144	7	7	4	3	3	13	5
Type of biopsy tissue
Nodal	122	0	0	0	5	19	14	15
Extranodal	117	13	7	6	2	7	11	4
IPI at first diagnosis
0 ~ 1	56	3	1	0	2	5	3	N/A
2 ~ 3	134	8	5	4	2	15	17	N/A
4 ~ 5	49	2	1	2	3	6	5	N/A
First chemotherapy regimen
R-CHOP or R-CHOP-like	228	13	0	6	7	26	25	9
Other or N/A	11	0	7	0	0	0	0	10

Abbreviations: DLBCL, NOS Diffuse Large B cell Lymphoma, Not Otherwise Specified, PMBCL Primary Mediastinal B-cell Lymphoma, PCNSL Primary Central Nervous System Lymphoma, PCDLBCL-LT Primary Cutaneous Diffuse Large B Cell Lymphoma, Leg Type, HGBL, NOS High Grade B-Cell Lymphoma, Not Otherwise Specified, HGBL-DH/TH High-Grade B-cell Lymphomas harboring rearrangements of MYC and BCL2 and/or BCL6, tFL Transformed Follicular Lymphoma, GCB Germinal Center B-cell-like, IPI International Prognostic Index, R-CHOP Rituximab plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone;

ISSN: 1471-2407